Shanghai Serum Bio-Technology Co., Ltd. engages in research, development, production, operation, and sales of antitoxin and antivenom serum products for biotoxi...
CEC Capital advises Zhongkexinyang on 100-million-yuan private financing round
SHANGHAI SERUM BIO-TECHNOLOGY released its performance for the first three quarters, with a net profit attributable to the parent company of 64.21 million yuan, a year-on-year increase of 2.01%
Zhitong A-share lock-up release overview | September 11
SHANGHAI SERUM BIO-TECHNOLOGY released its semi-annual performance, with a net profit attributable to the parent company of 32.98 million yuan, a year-on-year increase of 2.07%
SHANGHAI SERUM BIO-TECHNOLOGY: Has not conducted research related to AIDS vaccines
"Small and Beautiful" Stocks Exposed, 21 Stocks Listed